About Us

Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers.

Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Immunotherapy is intended to “wake” the immune system so that it can recognize and destroy cancer cells.